Supplementary Tables 1-8 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Autor: Johanna C. Bendell, Eric Laille, Kejian Liu, Aaron Nguyen, Jorge DiMartino, Gordon L. Bray, Patricia M. LoRusso, Miguel Martin, W. Jeff Edenfield, Jose A. Lopez-Martin, Ron H.J. Mathijssen, Bert O'Neil, Christophe Le Tourneau, Nicolas Isambert, Jan H.M. Schellens, Pamela N. Munster, Elisabeth I. Heath, Drew W. Rasco, Daniel D. Von Hoff
Rok vydání: 2023
Popis: Table S1. CC-486 Plus Carboplatin Dose Levels in Part 1 Arm A Table S2. CC-486 Plus nab-Paclitaxel Dose Levels in Part 1 Arm B Table S3. CC-486 Dose Levels in Part 1 Arm C Table S4. Number of Patients With Treatment Emergent Adverse Events for Part 1 Table S5. Number of Patients With Treatment-Emergent Adverse Events in Any Treatment Arm in Part 2 Table S6. Mean CC-486 Plasma Pharmacokinetic Parameters Table S7. Efficacy of CC-486 Alone or in Combination With Carboplatin or nab-Paclitaxel in Part 2 Table S8. Prior Treatment History of NPV Patients
Databáze: OpenAIRE